Clinical outcomes of aortic arch hybrid repair in a real-world single-center experience

2020 ◽  
Vol 72 (3) ◽  
pp. 813-821
Author(s):  
Tony R. Soares ◽  
Ryan Melo ◽  
Pedro Amorim ◽  
Augusto Ministro ◽  
Gonçalo Sobrinho ◽  
...  
Keyword(s):  
Aortic Arch ◽  
Clinical Outcomes ◽  
Real World ◽  
Single Center ◽  
Single Center Experience ◽  
Hybrid Repair

scholarly journals Real-World Clinical Outcomes in Elderly Chinese Patients with Multiple Myeloma: A Single-Center Experience

2018 ◽  
Vol 24 ◽  
pp. 5887-5893
Author(s):  
Xifeng Qian ◽  
Heng Chen ◽  
Jun Xia ◽  
Jing Wang ◽  
Xin Zhou ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Clinical Outcomes ◽  
Real World ◽  
Chinese Patients ◽  
Single Center ◽  
Single Center Experience ◽  
Elderly Chinese

Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold implantation in a real-world population: A single-center experience

2015 ◽  
Vol 16 (8) ◽  
pp. 461-464 ◽  
Author(s):  
Charis Costopoulos ◽  
Matthew C. Crowson ◽  
Adam J. Brown ◽  
Denise M. Braganza ◽  
Martin R. Bennett ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Real World ◽  
World Population ◽  
Single Center ◽  
Bioresorbable Vascular Scaffold ◽  
Single Center Experience ◽  
Vascular Scaffold

scholarly journals Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience

2021 ◽  
pp. 089719002110282
Author(s):  
Karan Raja ◽  
Nicole Daniel ◽  
Susan Morrison ◽  
Ruben Patel ◽  
Jessica Gerges ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Clinical Status ◽  
Rank Test ◽  
Cytokine Release ◽  
Cytokine Release Syndrome ◽  
Single Center ◽  
Post Dose ◽  
Single Center Experience ◽  
Signed Rank Test ◽  
The Impact

Background: Tocilizumab is an interleukin-6 receptor antagonist hypothesized to blunt the uncontrolled immune response, cytokine release syndrome, in severe COVID-19 and prevent attributable morbidity and mortality. Objective: The objective of this study was to assess the impact of tocilizumab on clinical outcomes in COVID-19-associated cytokine release syndrome. Methods: Single-center, retrospective cohort study assessing sixty-nine adult patients receiving tocilizumab for suspected COVID-19 cytokine release syndrome. The primary outcome was change in WHO clinical status scale on day seven post-dose analyzed using the Wilcoxon signed rank test. Secondary outcomes assessed impact of timing of administration on clinical outcome. Safety analyses included development of neutropenia, thrombocytopenia, transaminitis, and sepsis within 7 days post-dose. Statistical analyses were conducted using Microsoft Excel. Results: No aggregate clinical change was found between day 0 and day 7. Eleven patients improved, twenty-seven worsened, and thirty-one showed no change. Clinical outcomes were weakly correlated with time from symptom onset (rs = 0.21; p = 0.08) or hospital admission (rs = -0.08; p = 0.49) to dose. In-hospital mortality was 63%. Sepsis was diagnosed in 21 patients, five of which were post-dose. Transaminitis, neutropenia, and thrombocytopenia occurred in seven, one, and six patients, respectively. Conclusion: Tocilizumab did not appear to influence clinical outcomes in our study population, irrespective of timing of administration. Adverse events were not considered drug-related.

Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry

2018 ◽  
Vol 19 (5) ◽  
pp. 521-525 ◽  
Author(s):  
Rik Rozemeijer ◽  
Daniela Benedetto ◽  
Adriaan O. Kraaijeveld ◽  
Michiel Voskuil ◽  
Mèra Stein ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Real World ◽  
Diabetic Patients ◽  
Single Center
Sign in / Sign up

Export Citation Format

Share Document